drugset / Trial / NCT00591292

Phase I Study in Advanced Solid Tumors

NCT00591292 ↗

Phase 1 Completed 22 enrolled Alaunos Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

Dose escalating study of orally administered indibulin at twice daily schedule in subjects with solid tumors.

Timeline

Start
2007-07-02
Primary completion
2009-02-17
Completion
2009-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject indibulin Small molecule — —

Indications